Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest announcement is out from Pacific Edge Limited ( (PFGTF) ).
Pacific Edge Limited has announced the appointment of Simon Richard Flood as an Independent Director, as per the NZX Listing Rules. The Board has assessed his independence based on the NZX Corporate Governance Code and determined that there are no conflicts of interest that could compromise his ability to act independently. This appointment is expected to strengthen the company’s governance structure, potentially enhancing its market position and stakeholder confidence.
More about Pacific Edge Limited
Pacific Edge Limited is a global cancer diagnostics company specializing in the development and commercialization of bladder cancer diagnostic and prognostic tests. Headquartered in Dunedin, New Zealand, the company offers its Cxbladder suite of non-invasive genomic urine tests globally, with operations in New Zealand and the USA. These tests are designed for risk stratification of urothelial cancer, improving patient experience and clinical efficiency. Cxbladder is supported by extensive research and is included in the American Urological Association’s Microhematuria Guideline.
Find detailed analytics on PFGTF stock on TipRanks’ Stock Analysis page.